IGM Biosciences, Inc.

IGMS

US4495851085

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 05/07/2024 BST			5-day change	1st Jan Change
6.28 ^USD	-2.64%		-8.59%	-24.43%

07-01	IGM Biosciences, Inc.(NasdaqGS:IGMS) added to Russell Microcap Growth Index	CI
07-01	IGM Biosciences, Inc.(NasdaqGS:IGMS) added to Russell 3000 Growth Index	CI

IGM Biosciences, Inc.(NasdaqGS:IGMS) added to Russell Microcap Growth Index

July 30, 2024

Latest news about IGM Biosciences, Inc.

IGM Biosciences, Inc.(NasdaqGS:IGMS) added to Russell Microcap Growth Index	06-30	CI
IGM Biosciences, Inc.(NasdaqGS:IGMS) added to Russell 3000 Growth Index	06-30	CI
IGM Biosciences, Inc.(NasdaqGS:IGMS) added to Russell 3000E Growth Index	06-30	CI
IGM Biosciences, Inc.(NasdaqGS:IGMS) added to Russell 2000 Growth Index	06-30	CI
IGM Biosciences, Inc.(NasdaqGS:IGMS) added to Russell 2500 Growth Index	06-30	CI
IGM Biosciences, Inc.(NasdaqGS:IGMS) added to Russell Small Cap Comp Growth Index	06-30	CI
RBC Cuts Price Target on IGM Biosciences to $20 From $21, Keeps Outperform, Speculative Risk	05-09	MT
Earnings Flash (IGMS) IGM BIOSCIENCES Posts Q1 Collaboration Revenue $497,000	05-08	MT
IGM Biosciences, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024	05-08	CI
IGM Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
IGM Biosciences, Sanofi Narrow Partnership to Focus on Potential Immunology and Inflamation Targets	04-17	MT
IGM Biosciences, Inc. Announces Refocusing of Sanofi Collaboration	04-17	CI
North American Morning Briefing : Stocks Set for -2-	03-28	DJ
HC Wainwright Adjusts IGM Biosciences Price Target to $12 From $7, Maintains Neutral Rating	03-12	MT
Earnings Flash (IGMS) IGM BIOSCIENCES Reports Q4 Revenue $651,000	03-07	MT
Igm Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-07	CI
IGM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07	CI
North American Morning Briefing : Stock Futures -2-	02-12	DJ
RBC Upgrades IGM Biosciences to Outperform From Sector Perform, Boosts Price Target to $21 From $9; Speculative Risk Kept	02-09	MT
Transcript : IGM Biosciences, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 11:15 AM	01-10
North American Morning Briefing : Stock Futures -2-	12-18	DJ
BofA Securities Downgrades IGM Biosciences to Neutral From Buy, Adjusts Price Target to $8 From $20	12-15	MT
IGM Biosciences, Inc.(NasdaqGS:IGMS) dropped from NASDAQ Biotechnology Index	12-15	CI
North American Morning Briefing : Futures Pause -2-	12-08	DJ
HC Wainwright Downgrades IGM Biosciences to Neutral From Buy, Cuts Price Target to $7 From $11	12-07	MT

IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Companyâs pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Companyâs development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.

Sector

Biotechnology & Medical Research

Calendar

04/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for IGM Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6.28 USD

Average target price

21.4 USD

Spread / Average Target

+240.76%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
IGM BIOSCIENCES, INC.	-24.43%	371M
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+17.75%	112B
ARGENX SE	+18.69%	25.91B
BIONTECH SE	-24.11%	19.33B
GENMAB A/S	-17.94%	16.17B
BEIGENE, LTD.	-18.47%	15.6B
WUXI APPTEC CO., LTD.	-47.75%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14B

Bio Therapeutic Drugs